AU2001287898A1 - Pyrazolopyridines and pyrazolopyridazines as antidiabetics - Google Patents
Pyrazolopyridines and pyrazolopyridazines as antidiabeticsInfo
- Publication number
- AU2001287898A1 AU2001287898A1 AU2001287898A AU8789801A AU2001287898A1 AU 2001287898 A1 AU2001287898 A1 AU 2001287898A1 AU 2001287898 A AU2001287898 A AU 2001287898A AU 8789801 A AU8789801 A AU 8789801A AU 2001287898 A1 AU2001287898 A1 AU 2001287898A1
- Authority
- AU
- Australia
- Prior art keywords
- pyrazolopyridazines
- pyrazolopyridines
- antidiabetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NMEPLWZDUIIAAC-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridazine Chemical class C1=NN=C2C=NNC2=C1 NMEPLWZDUIIAAC-UHFFFAOYSA-N 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023361 | 2000-09-22 | ||
| GB0023361A GB0023361D0 (en) | 2000-09-22 | 2000-09-22 | Novel compounds |
| GB0023358A GB0023358D0 (en) | 2000-09-22 | 2000-09-22 | Novel compounds |
| GB0023358 | 2000-09-22 | ||
| GB0107391 | 2001-03-23 | ||
| GB0107391A GB0107391D0 (en) | 2001-03-23 | 2001-03-23 | Novel compounds |
| GB0110671 | 2001-05-01 | ||
| GB0110671A GB0110671D0 (en) | 2001-05-01 | 2001-05-01 | Novel compounds |
| GB0112799 | 2001-05-25 | ||
| GB0112799A GB0112799D0 (en) | 2001-05-25 | 2001-05-25 | Novel compounds |
| PCT/GB2001/004186 WO2002024694A1 (en) | 2000-09-22 | 2001-09-19 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001287898A1 true AU2001287898A1 (en) | 2002-04-02 |
Family
ID=27515980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001287898A Abandoned AU2001287898A1 (en) | 2000-09-22 | 2001-09-19 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7109199B2 (en) |
| EP (1) | EP1319001A1 (en) |
| JP (1) | JP2004509891A (en) |
| AU (1) | AU2001287898A1 (en) |
| WO (1) | WO2002024694A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024694A1 (en) * | 2000-09-22 | 2002-03-28 | Smithkline Beecham, P.L.C. | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
| EP2295550A3 (en) | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| GB0128287D0 (en) * | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| GB0207246D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207249D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7541378B2 (en) * | 2002-07-25 | 2009-06-02 | Pfizer Italia S.R.L. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| ES2214976B1 (en) * | 2003-03-14 | 2005-12-16 | J. URIACH & CIA S.A. | "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS". |
| CL2004000398A1 (en) | 2003-02-27 | 2005-03-18 | Uriach Y Compania S A J | COMPOUNDS DERIVED FROM PIRAZOLOPIRIDINAS, ITS SALTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT DISEASES MEDIATED BY P38 KINASES, ESPECIALLY BY CITOCINES, TNF-ALFA, IL-1, IL-6 AND / OR IL-8, SUCH AS DISEASE |
| ES2214150B1 (en) * | 2003-02-27 | 2005-12-01 | J. URIACH & CIA S.A. | "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS". |
| US20050014680A1 (en) * | 2003-04-15 | 2005-01-20 | Crabtree Gerald R. | Methods and compositions for enhancing neuron growth and survival |
| KR100803796B1 (en) | 2003-06-17 | 2008-02-14 | 화이자 인코포레이티드 | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline reuptake inhibitors |
| BRPI0411891A (en) | 2003-06-27 | 2006-08-29 | Pfizer Prod Inc | pyrazol [3,4-b] pyridin-6-ones as gsk-3 inhibitors |
| EP1641455B1 (en) * | 2003-06-27 | 2008-08-06 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| KR20070053237A (en) * | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | Pyrrolo-pyridine kinase modulator |
| EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| WO2007098826A2 (en) * | 2006-01-18 | 2007-09-07 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| DE102006005180A1 (en) * | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl derivatives |
| CL2008000119A1 (en) | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
| AU2008282156B2 (en) * | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| MY158994A (en) | 2008-02-04 | 2016-11-30 | Mercury Therapeutics Inc | Ampk modulators |
| JP5658688B2 (en) * | 2009-01-28 | 2015-01-28 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Carboxamide compounds and methods of use thereof |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| KR102129114B1 (en) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | A compound having TrkA inhibitory activity, and a pharmaceutical composition for preventing or treating pain containing the compound as an active ingredient |
| AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
| CN118126038B (en) * | 2024-05-08 | 2024-07-12 | 烟台大学 | Pyrazolopyridine derivative, and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2238400A1 (en) * | 1972-08-04 | 1974-02-14 | Hoechst Ag | Basic azo dyes from 3-amino 1H-pyrazolo (3,4-b) pyridines - for use on polyacrylonitrile or acid-modified polyester fibres |
| US4361568A (en) * | 1981-04-28 | 1982-11-30 | Sterling Drug Inc. | 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use |
| WO1997041854A1 (en) | 1996-05-07 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same |
| BR0104424A (en) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Pyrazole compositions useful as erk inhibitors |
| AU4878601A (en) * | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| WO2002024694A1 (en) * | 2000-09-22 | 2002-03-28 | Smithkline Beecham, P.L.C. | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
-
2001
- 2001-09-19 WO PCT/GB2001/004186 patent/WO2002024694A1/en not_active Ceased
- 2001-09-19 AU AU2001287898A patent/AU2001287898A1/en not_active Abandoned
- 2001-09-19 EP EP01967523A patent/EP1319001A1/en not_active Withdrawn
- 2001-09-19 US US10/381,292 patent/US7109199B2/en not_active Expired - Fee Related
- 2001-09-19 JP JP2002529104A patent/JP2004509891A/en not_active Withdrawn
-
2006
- 2006-06-06 US US11/422,338 patent/US7297792B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002024694A1 (en) | 2002-03-28 |
| US7109199B2 (en) | 2006-09-19 |
| US20040019052A1 (en) | 2004-01-29 |
| US7297792B2 (en) | 2007-11-20 |
| EP1319001A1 (en) | 2003-06-18 |
| JP2004509891A (en) | 2004-04-02 |
| US20060223800A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001287898A1 (en) | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | |
| AU2002235128A1 (en) | Expression miniarrays and uses thereof | |
| AU2001260327A1 (en) | Chair | |
| AU2001213236A1 (en) | Mini-cyclone biocollector and concentrator | |
| AU2001264313A1 (en) | Pyrazolopyridine compounds and use thereof as drugs | |
| AU2001280599A1 (en) | Compounds and methods | |
| AU2001253418A1 (en) | Compounds and methods | |
| AU2002219135A1 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors | |
| AU2002211717A1 (en) | Stresscopins and their uses | |
| AU2001272011A1 (en) | Siderophores-producing bifidobacteria thereby and uses thereof | |
| AU2001261750A1 (en) | Laminate and its use | |
| AU2001243394A1 (en) | Compounds and methods | |
| AU2002222485A1 (en) | Multi-purpose structure | |
| AU2001292936A1 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
| AU2001295185A1 (en) | Multiplexing-interleaving and demultiplexing-deinterleaving | |
| AUPQ872300A0 (en) | Compounds and methods | |
| AU2002213429A1 (en) | Antiviral methods and compounds | |
| AU2001234178A1 (en) | Modified bdnf | |
| AU2002227925A1 (en) | Human beta-defensin-3 | |
| AU2001278951A1 (en) | Compounds and methods | |
| AU2001252200A1 (en) | Chair | |
| AU4432001A (en) | Trityl-type compounds and their use | |
| AU2001252671A1 (en) | Pyridobenzodiazine derivatives and processes for the preparation thereof | |
| AU2001261317A1 (en) | Immunostimulant compositions and associated methods | |
| AU2002235277A1 (en) | Compounds and methods |